data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

Español

India

Italiano

Français

My Account

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Research

My Stocks

Tools

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Trade Ideas

Unusual Options Activity

Short Interest

Calculators

Forex Profit Calculator

100x Options Profit Calculator

-

––%

-

––%

-

––%

-

––%

-

––%

-

––%

-

––%

Adaptimmune Therapeutics PLC

(NASDAQ:ADAP)

$0.76

0[0.00%]

Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here

$0.7541

-0.0059[-0.78%]

Open-	Close-
Vol / Avg.0 / 590.046K	Mkt Cap171.891M
Day Range- - -	52 Wk Range0.680 - 2.645

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, September 19, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - 6 days ago

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Thursday, September 07, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Sep 7, 2023, 1:55PM

Friday, August 25, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Aug 25, 2023, 5:31PM

Thursday, August 24, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Aug 24, 2023, 5:32PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
Analyst Expectations for Adaptimmune Therapeutics's Future
Benzinga Insights - Aug 10, 2023, 8:00AM
Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1
Benzinga Newsdesk - Aug 10, 2023, 7:20AM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 10, 2023, 4:47AM

Monday, August 07, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 7, 2023, 12:13PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Tuesday, June 06, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Jun 6, 2023, 1:54PM

Monday, June 05, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Jun 5, 2023, 4:12AM

Friday, May 26, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - May 26, 2023, 7:06AM

Friday, May 12, 2023

Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Adaptimmune Therapeutics Q1 Earnings
Benzinga Insights - May 12, 2023, 7:35AM
Adaptimmune Therapeutics Q1 EPS $0.00 Up From $(0.05) YoY, Sales $47.60M Up From $3.58M YoY
Benzinga Newsdesk - May 12, 2023, 7:32AM

Thursday, May 11, 2023

Earnings Preview For Adaptimmune Therapeutics
Benzinga Insights - May 11, 2023, 10:02AM

Monday, April 17, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 17, 2023, 7:07AM

Tuesday, April 11, 2023

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Apr 11, 2023, 9:57AM
GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The Transition
Benzinga Newsdesk - Apr 11, 2023, 8:15AM

Wednesday, April 05, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Apr 5, 2023, 2:28PM

Tuesday, March 07, 2023

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh - Mar 7, 2023, 7:34PM

Monday, March 06, 2023

Why Is TCR2 Therapeutics Stock Trading Higher Today?
Ye Kuang - Mar 6, 2023, 2:01PM
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 6, 2023, 1:25PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 6, 2023, 12:31PM
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Mar 6, 2023, 11:17AM
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Vandana Singh - Mar 6, 2023, 11:08AM
Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.
Benzinga Newsdesk - Mar 6, 2023, 8:25AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Mar 6, 2023, 8:06AM
Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M Estimate
Benzinga Newsdesk - Mar 6, 2023, 6:47AM
Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid Tumors
Benzinga Newsdesk - Mar 6, 2023, 6:04AM
Earnings Scheduled For March 6, 2023
Benzinga Insights - Mar 6, 2023, 4:52AM

Friday, March 03, 2023

Adaptimmune Therapeutics's Earnings Outlook
Benzinga Insights - Mar 3, 2023, 11:00AM

Tuesday, January 31, 2023

Adaptimmune Therapeutics Says On Jan 27, Received Notice Of Termination Of Amended & Restated Research Collaboration & License Agreement Dated Jan 13, 2020
Benzinga Newsdesk - Jan 31, 2023, 4:32PM
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jan 31, 2023, 6:00AM

Monday, January 09, 2023

Publication Of Data From Adaptimmune's Completed Phase 1 Trial With Afami-cel In Nature Medicine Demonstrating An Acceptable Safety Profile And Encouraging Responses In Synovial Sarcoma
Benzinga Newsdesk - Jan 9, 2023, 8:24AM

Thursday, January 05, 2023

Expert Ratings for Adaptimmune Therapeutics
Benzinga Insights - Jan 5, 2023, 12:00PM
Adaptimmune Therapeutics shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and $10 price target.
Bill Haddad - Jan 5, 2023, 11:20AM
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga Insights - Jan 5, 2023, 10:01AM
EF Hutton Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Jan 5, 2023, 4:46AM

Tuesday, January 03, 2023

Adaptimmune Therapeutics shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy and announced a $5 price target.
Benzinga Newsdesk - Jan 3, 2023, 8:28AM
Guggenheim Upgrades Adaptimmune Therapeutics to Buy, Announces $5 Price Target
Benzinga Newsdesk - Jan 3, 2023, 7:53AM

Friday, December 30, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:33PM
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 30, 2022, 4:32PM

Friday, December 23, 2022

Adaptimmune Announces Initiation Of Biologics License Application Submission For Afami-Cel, Its First-Gen Engineered TCR T-Cell Therapy Targeting MAGE-A4, For The Treatment Of Synovial Sarcoma
Benzinga Newsdesk - Dec 23, 2022, 1:23PM

Friday, November 25, 2022

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Lisa Levin - Nov 25, 2022, 2:34AM

Friday, November 18, 2022

Adaptimmune Therapeutics Announces Data From Cohort 1 Of SPEARHEAD-1 Trial At CTOS Continue To Support BLA Submission For Afami-cel In Synovial Sarcoma
Benzinga Newsdesk - Nov 18, 2022, 8:04AM

Monday, November 14, 2022

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3
Benzinga Newsdesk - Nov 14, 2022, 7:36AM

Wednesday, November 09, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga Insights - Nov 9, 2022, 10:05AM

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap